BJDX logo

BLUEJAY DIAGNOSTICS INC

BJDXNASDAQ
๐Ÿ† #5183 by market capUS Equity
$1.74โ–ผ $0.29 (โˆ’14.29%)
Market closed ยท at close
๐Ÿ””
Track BJDX
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ผ 14.3%
7dโ–ผ 37.9%
14dโ–ผ 20.9%
30dโ–ผ 25.6%
ytdโ–ผ 83.9%
1yโ–ผ 91.2%
๐ŸฆMarket Cap
$8M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-100.0%
Declining
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
โ€”
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$1.71 โ€“ $1.74
52-Week Range
$1.70 โ€“ $28.00
Volume (shares)
286
Avg Volume (shares)
โ€”
Shares Outstanding
4.5M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
โ€”
P/S Ratio
โ€”
EPS (TTM)
$-185.53
Dividend Yield
โ€”
BJDX logo

BLUEJAY DIAGNOSTICS INC

BJDX
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About BLUEJAY DIAGNOSTICS INC

Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.